MedTrace Logo

Pilot Study of Betahistine Dihydrochloride in the Treatment of Major Depression With Atypical Features

NCT00585585 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2017-07-25

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine a dose of the investigational drug betahistine dihydrochloride that is both well tolerated and potentially effective in treating the symptoms of atypical depression. Atypical depression is characterized by the ability of the person's mood to improve temporarily in response to positive events, as well as features such as increased appetite, increased sleep and severe fatigue.

Conditions

  • Recurrent Major Depressive Disorder With Atypical Features

Interventions

DRUG

betahistine dihydrochloride

oral, 50-300 mg, daily

Sponsors & Collaborators

  • University of Cincinnati

    lead OTHER

Principal Investigators

  • Erik Nelson, MD · University of Cincinnati

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-07-31
Primary Completion
2011-01-31
Completion
2011-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00585585 on ClinicalTrials.gov